Over the past four years, the landscape of alopecia areata has changed dramatically. What was once a condition with limited and often unpredictable treatment options has entered an era of evidence-based targeted therapies. Baricitinib helped pave the way for additional approvals, while also accelerating research into the biology of autoimmune hair loss.
Perhaps most importantly, baricitinib changed expectations. Patients, physicians, researchers, and regulators began to view significant hair regrowth not as an exception, but as a realistic treatment goal for many individuals with severe disease.
Four years later, we continue to learn about long-term outcomes, durability of response, and how best to personalize treatment. But June 13, 2022 will always be remembered by me as the day alopecia areata treatment entered a new era.
Here’s to the patients who participated in the clinical trials, the researchers who advanced the science, and the many individuals with alopecia areata who continue to inspire progress every day!
